News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Global Coalition for Adaptive Research (GCAR) Selects DelMar Pharmaceuticals` VAL-083 to Participate in the GBM AGILE Pivotal Study, an Adaptive Clinical Trial Platform in Glioblastoma Multiforme

Al's Comment:

 GBM Agile is the next generation of clinical trial - where multiple drugs are tested against a common control arm, instead of each trial having it's own control arm.  They selected Val-083 to test in one of the arms of the trial. Val-083 is an experimental chemotherapy, similar to Temodar but it works on a different area of the DNA so the MGMT repair enzyme can not undo the damage it does to the tumor. In theory, it should not matter if the MGMT is methylated or unmethylated.  With Temodar, if your MGMT is unmethylated, there is a much less chance that it will help.  This is probably the best and fastest path to FDA approval for Val-083. I wish them luck.


Posted on: 06/13/2020

Global Coalition for Adaptive Research (GCAR) Selects DelMar Pharmaceuticals' VAL-083 to Participate in the GBM AGILE Pivotal Study, an Adaptive Clinical Trial Platform in Glioblastoma Multiforme

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740